IL315893A - 5-MEO-DMT for use in the treatment of postpartum depression - Google Patents

5-MEO-DMT for use in the treatment of postpartum depression

Info

Publication number
IL315893A
IL315893A IL315893A IL31589324A IL315893A IL 315893 A IL315893 A IL 315893A IL 315893 A IL315893 A IL 315893A IL 31589324 A IL31589324 A IL 31589324A IL 315893 A IL315893 A IL 315893A
Authority
IL
Israel
Prior art keywords
dmt
meo
treatment
postpartum depression
postpartum
Prior art date
Application number
IL315893A
Other languages
English (en)
Hebrew (he)
Inventor
Theis Terwey
Conor Burke
Naoise Gaffney
Original Assignee
Gh Res Ireland Limited
Theis Terwey
Conor Burke
Naoise Gaffney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited, Theis Terwey, Conor Burke, Naoise Gaffney filed Critical Gh Res Ireland Limited
Priority claimed from PCT/EP2023/057873 external-priority patent/WO2023186826A1/en
Publication of IL315893A publication Critical patent/IL315893A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL315893A 2022-03-27 2023-03-27 5-MEO-DMT for use in the treatment of postpartum depression IL315893A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22000086 2022-03-27
EP22000083 2022-03-27
EP23153939 2023-01-30
EP23153995 2023-01-30
PCT/EP2023/057873 WO2023186826A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression

Publications (1)

Publication Number Publication Date
IL315893A true IL315893A (en) 2024-11-01

Family

ID=93294635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315893A IL315893A (en) 2022-03-27 2023-03-27 5-MEO-DMT for use in the treatment of postpartum depression

Country Status (7)

Country Link
US (1) US20250221963A1 (https=)
EP (1) EP4499079A1 (https=)
JP (1) JP2025511072A (https=)
KR (1) KR20240167885A (https=)
AU (1) AU2023246547A1 (https=)
CA (1) CA3255644A1 (https=)
IL (1) IL315893A (https=)

Also Published As

Publication number Publication date
JP2025511072A (ja) 2025-04-15
AU2023246547A1 (en) 2024-11-07
CA3255644A1 (en) 2023-10-05
US20250221963A1 (en) 2025-07-10
EP4499079A1 (en) 2025-02-05
KR20240167885A (ko) 2024-11-28

Similar Documents

Publication Publication Date Title
EP4066837A4 (en) USE OF BI853520 IN THE TREATMENT OF CANCER
ZA202204809B (en) 5-ht2a agonists for use in treatment of depression
IL308221A (en) Preparations and methods for treating depression
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
ES3064658T3 (en) Recombinant alpha-a-crystallin and combinations for use in the treatment of cancer
IL315893A (en) 5-MEO-DMT for use in the treatment of postpartum depression
IL282718A (en) Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases
PL4048229T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu zapalenia pęcherza moczowego o różnej etiologii
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
PL3797771T3 (pl) Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
IL312428A (en) Use of Maribavir for treatment and their treatment methods
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
AU2023902805A0 (en) Combination for use in the treatment of glioma
CA3304484A1 (en) Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
HK40074743A (en) Methylthioninium for use in the treatment of synaptopathies
HK40088920A (en) Methylthioninium compounds for use in the treatment of covid-19